StockNews.AI
LLY
Forbes
216 days

Buy, Sell, Or Hold LLY Stock At $750?

1. Eli Lilly's stock dropped 6% due to slower obesity drug sales growth. 2. Q4 revenue forecast adjusted down by 5%, missing analysts' estimates. 3. LLY projects 2024 revenue of $45 billion, reflecting 32% growth. 4. Strong 2025 outlook anticipates revenue between $58 billion and $61 billion. 5. Potential approval for orforglipron could enhance future sales growth.

5m saved
Insight
Article

FAQ

Why Bearish?

The significant drop and revenue cuts create short-term investor concern, similar to past downturns during slow growth announcements.

How important is it?

The article discusses Eli Lilly's revenue adjustments and future growth prospects, directly impacting LLY's investment outlook.

Why Long Term?

Strong projected growth for 2025 and potential approvals suggest recovery over time, akin to previous rebounds following initial declines.

Related Companies

Related News